Compares two scan types for finding neuroblastoma in children
Tests two imaging scans in children with suspected or confirmed neuroblastoma.
Plain-language title generated from the registry record
Registry title: Clinical Application Study of [123I]Metaiodobenzylguanidine and Somatostatin Receptor-Targeted Imaging in the Diagnosis and Staging of Neuroblastoma
Key facts
- Where
- Nanjing, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and young people up to 18 years with neuroblastoma, confirmed or strongly suspected, who are planned to have imaging scans.
- Age
- 0 to 18 years
- Sex
- All sexes can join.
- Disease stage
- Neuroblastoma confirmed by tissue examination or strongly suspected, with at least one measurable lesion on CT or MRI.
- Earlier treatment
- Cannot join if they had high-dose chemotherapy or radiotherapy, radionuclide therapy, or took part in another interventional trial in the past 4 weeks.
Main reasons for not taking part
- Severe allergy to the radioactive substance or imaging probe to be used
- Pregnancy or breastfeeding
- Severe or uncontrolled heart, lung, liver or kidney failure, or severe active infection
- Blood counts not yet recovered: Hb < 90 g/L, ANC < 1.5 × 10⁹/L, platelets < 100 × 10⁹/L
- Cannot complete PET/CT scans, for example severe claustrophobia or cannot lie on the back for 30 minutes or more
Read by machine on 12 November 2026.
Where in China
- Nanjing First HospitalNanjing, ChinaContact: Ying ZhangTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Nanjing First Hospital, Nanjing Medical University
- Trial code
- NCT07064746
- Record updated
- 21 July 2025
- Original description
The goal of this prospective observational study is to evaluate the diagnostic performance of ¹²³I-MIBG SPECT/CT and SSTR PET in Chinese children with suspected or confirmed neuroblastoma (NB). The main questions it aims to answer are:Read full original descriptionShow less
Clinical Application Study of [123I]Metaiodobenzylguanidine and Somatostatin Receptor-Targeted Imaging in the Diagnosis and Staging of Neuroblastoma
The goal of this prospective observational study is to evaluate the diagnostic performance of ¹²³I-MIBG SPECT/CT and SSTR PET in Chinese children with suspected or confirmed neuroblastoma (NB). The main questions it aims to answer are:
* What are the sensitivity and specificity of each modality-alone and combined-for initial staging and for detecting relapse or metastasis? * Can SSTR-targeted PET reliably identify MIBG-negative NB lesions and help select candidates for peptide-receptor radionuclide therapy (PRRT)?
Pediatric patients (≤18 years) undergoing routine evaluation for NB will receive both imaging studies; results will be correlated with histopathology, clinical course, and 24-month follow-up.
Inclusion: Ages 0-18 years, any sex; Histologically confirmed or clinically highly suspected neuroblastoma with planned imaging assessment; At least one measurable lesion on conventional imaging such as CT or MRI; ECOG performance status 0-2 and an expected survival of ≥3 months; Hematologic, hepatic, and renal function meeting the following criteria: Hb ≥ 90 g/L, ANC ≥ 1.5 × 10⁹/L, platelets ≥ 100 × 10⁹/L, ALT/AST ≤ 2.5 × ULN, Cr ≤ 1.5 × ULN; Informed consent signed by the subject or legal guardian.
Exclusion: Receipt of high-dose chemotherapy/radiotherapy, radionuclide therapy, or participation in other interventional clinical trials within the past 4 weeks; Known history of severe allergy to the radioactive isotope or molecular probe components to be used; Severe or uncontrolled cardiac, pulmonary, hepatic, or renal insufficiency, or active severe infection; Bone marrow suppression not yet recovered (Hb < 90 g/L, ANC < 1.5 × 10⁹/L, platelets < 100 × 10⁹/L); Pregnancy or lactation; Inability to complete imaging examinations such as PET/CT (e.g., severe claustrophobia, inability to lie supine for ≥ 30 min); Any other situation deemed inappropriate for enrollment by the investigator.